Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously. [Source]
Publication Date:Origin: nytimes.com
Category: Drugs (Pharmaceuticals)
Topics: unanimously, concluded, panel, risks, outweigh, Lilly, donanemab, treatment, benefits, modest, Alzheimer’s, Approval, Endorses, Experts, Panel, Advisory
Source: https://www.nytimes.com/2024/06/10/health/alzheimers-treatment-donanemab.html